Selection of Anti-TIGIT Affibody Molecules Blocking the Interaction between TIGIT and CD155

Abstract

T cell immunoglobulin and ITIM domain (TIGIT) is an immune checkpoint receptor expressed on T and NK cells that, upon interaction with its ligand CD155, suppresses immune cell activation. Tumor cells sometimes upregulate CD155 to evade detrimental immune reactions, and TIGIT is therefore an attractive target for the development of novel checkpoint inhibitor therapies. TIGIT has also been shown to be upregulated on tumor-infiltrating lymphocytes (TILs), enabling imaging of TILs for patient stratification for immune checkpoint therapy. Here, we have selected so-called affibody molecules targeting TIGIT from a combinatorial affibody library displayed on the surface ofEscherichia coli. The two most promising candidates had equilibrium dissociation constants (KD values) of 2.5 and 6.5 nM, and were found to specifically interact with TIGIT-expressing cells. Furthermore, the affibody candidates were found to successfully block the interaction between TIGIT and CD155, suggesting future application as immune checkpoint inhibitors. Using an ensemble of general language models for in silico evolution, a variant with a 4.4 °C increased melting temperature could be derived, albeit with a 2-fold weaker affinity. The promising results justify further development of the anti-TIGIT affibodies for in vivo TIL-imaging and immune checkpoint therapy.

Imaging of ROR1 expression in tumors using radiolabeled affibody molecules
Cornelia Westerberg, Tianqi Xu, Maria Marth +8
European Journal of Nuclear Medicine and Molecular Imaging1 Aug 2026Peer-reviewedCC BY 4.0Full text1 citedMedical imaging & radiologyPMC
Small molecules targeting ARF1 interaction with C9orf72:SMCR8:WDR41 complexes suppress its overactivation implicated in ALS/FTD
Emma Dixon, Fereshteh Azimian, Angelina Joby Chacko +4
Scientific Reports3 Oct 2026Peer-reviewedCC BY 4.0Full textNeurologyCrossref
A Structure-Based hERG Pose Selection Workflow Integrating Induced-Fit Docking, Shape Similarity, Interaction Fingerprints, and Molecular Dynamics
P. Neema, U. Ozuguzel, S. Najafian +1
bioRxiv7 Oct 2026PreprintAll rights reservedFull textPharmacology & toxicologybioRxiv
MYC-Hyperactivated Osteosarcoma Models Exhibit Resistance to Cabozantinib plus TIGIT Blockade
S. S. Kappa, T. Patel, B. Nirala +3
bioRxiv21 Sep 2026PreprintAll rights reservedFull textOncologybioRxiv
Retrospective analysis of LAG3, TIGIT, TIM3 and VISTA immune checkpoints expression in hip and knee periprosthetic joint infection
Nicole Lind Henriksen, Mats Bue, Christen Ravn +7
Scientific Reports19 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textSurgery & anaesthesiaCrossref

Cite

BibTeX RIS

BibTeX

@article{ehrenborg2026selection,
  title = {{Selection of Anti-TIGIT Affibody Molecules Blocking the Interaction between TIGIT and CD155}},
  author = {Linda Ehrenborg and Javad Garousi and Jie Zhang and Hans Grönlund and Torbjörn Gräslund},
  journal = {ACS Omega},
  year = {2026},
  month = oct,
  doi = {10.1021/acsomega.6c05539},
  url = {https://pubs.acs.org/acsodf/article/doi/10.1021/acsomega.6c05539/5455889/Selection-of-Anti-TIGIT-Affibody-Molecules},
  note = {CC BY 4.0},
}

RIS

TY  - JOUR
TI  - Selection of Anti-TIGIT Affibody Molecules Blocking the Interaction between TIGIT and CD155
AU  - Linda Ehrenborg
AU  - Javad Garousi
AU  - Jie Zhang
AU  - Hans Grönlund
AU  - Torbjörn Gräslund
PY  - 2026
DA  - 2026/10/22
JO  - ACS Omega
DO  - 10.1021/acsomega.6c05539
UR  - https://pubs.acs.org/acsodf/article/doi/10.1021/acsomega.6c05539/5455889/Selection-of-Anti-TIGIT-Affibody-Molecules
AB  - T cell immunoglobulin and ITIM domain (TIGIT) is an immune checkpoint receptor expressed on T and NK cells that, upon interaction with its ligand CD155, suppresses immune cell activation. Tumor cells sometimes upregulate CD155 to evade detrimental immune reactions, and TIGIT is therefore an attractive target for the development of novel checkpoint inhibitor therapies. TIGIT has also been shown to be upregulated on tumor-infiltrating lymphocytes (TILs), enabling imaging of TILs for patient stratification for immune checkpoint therapy. Here, we have selected so-called affibody molecules targeting TIGIT from a combinatorial affibody library displayed on the surface ofEscherichia coli. The two most promising candidates had equilibrium dissociation constants (KD values) of 2.5 and 6.5 nM, and were found to specifically interact with TIGIT-expressing cells. Furthermore, the affibody candidates were found to successfully block the interaction between TIGIT and CD155, suggesting future application as immune checkpoint inhibitors. Using an ensemble of general language models for in silico evolution, a variant with a 4.4 °C increased melting temperature could be derived, albeit with a 2-fold weaker affinity. The promising results justify further development of the anti-TIGIT affibodies for in vivo TIL-imaging and immune checkpoint therapy.
SN  - 2470-1343
ER  -

Abstract

Related

Cite